Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Cooperative Groups: past and future

R L Comis1

  • 1Eastern Cooperative Oncology Group, Allegheny Cancer Center, Pittsburgh, PA, USA. COMIS@auhs.edu

Cancer Chemotherapy and Pharmacology
|September 28, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2009
Same author

Future directions in the treatment of non-small cell lung cancer.

Seminars in oncology·2000
Same author

The role of oral etoposide in non-small cell lung cancer.

Drugs·2000
Same author

Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors.

Cancer·1998
Same author

Small-cell lung cancer: a perspective on the past and a preview of the future.

Oncology (Williston Park, N.Y.)·1998
Same author

Developing an AHC-MCO alliance for research and care.

Health care management review·1998
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026
Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
See all related articles

The National Cancer Institute (NCI) Cooperative Groups are adapting to shrinking funds and a changing healthcare landscape. They are implementing new strategies to enhance industry partnerships, international collaboration, and health outcomes research to maintain leadership in cancer clinical trials.

Area of Science:

  • Oncology
  • Clinical Trials
  • Health Services Research

Background:

  • The National Cancer Institute (NCI) Cooperative Groups have a long history of conducting cancer clinical trials.
  • Current challenges include shrinking government funding and evolving healthcare environments in the USA.
  • There is a need for Cooperative Groups to adapt their operational mechanisms to maintain leadership in cancer research.

Purpose of the Study:

  • To outline necessary adjustments for NCI Cooperative Groups to sustain their leadership in cancer clinical trials.
  • To propose new approaches addressing operational inefficiencies, funding shortfalls, and the need for enhanced collaboration.
  • To integrate health outcomes and economic measures into clinical trial protocols.

Main Methods:

  • Discussion and strategic planning among Cooperative Group leaders.

Related Experiment Videos

  • Focus on establishing improved industry contracts and fostering international cooperation.
  • Emphasis on greater involvement of third-party payers and integration of economic measures.

    • Main Results:

    • Cooperative Groups are developing new strategies to address identified deficiencies.
    • Proposed changes aim to enhance efficiency in executing large phase III studies.
    • New approaches will complement existing NCI structures while respecting group independence.

    Conclusions:

    • NCI Cooperative Groups are implementing changes to ensure continued leadership in cancer clinical trials.
    • These adjustments are expected to benefit patients, healthcare professionals, and the healthcare industry.
    • The goal is to remain at the forefront of cancer research and treatment evaluation into the 21st century.